{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:28:41Z","timestamp":1791264521360,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/2050-6511-14-38","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T02:22:36Z","timestamp":1375323756000},"source":"Crossref","is-referenced-by-count":65,"title":["Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance"],"prefix":"10.1186","volume":"14","author":[{"given":"Elizabeth","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashish K","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan Chinmaya","family":"Shatapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,1]]},"reference":[{"key":"150_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1192\/bjp.178.5.427","volume":"178","author":"LM Howard","year":"2001","unstructured":"Howard LM, Kumar R, Thornicroft G: Psychosocial characteristics and needs of mothers with psychotic disorders. Br J Psychiatry. 2001, 178: 427-32. 10.1192\/bjp.178.5.427.","journal-title":"Br J Psychiatry"},{"key":"150_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4088\/JCP.v66n0406","volume":"66","author":"K McKenna","year":"2005","unstructured":"McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A: Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005, 66: 444-449. 10.4088\/JCP.v66n0406.","journal-title":"J Clin Psychiatry"},{"key":"150_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2165\/00002018-200730030-00006","volume":"30","author":"D Coppola","year":"2007","unstructured":"Coppola D, Russo LJ, Kwarta RF, Varughese R, Schmider J: Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf. 2007, 30: 247-264. 10.2165\/00002018-200730030-00006.","journal-title":"Drug Saf"},{"key":"150_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/schbul\/sbn107","volume":"36","author":"S Gentile","year":"2010","unstructured":"Gentile S: Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010, 36: 518-544. 10.1093\/schbul\/sbn107.","journal-title":"Schizophr Bull"},{"key":"150_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1176\/appi.ajp.162.1.79","volume":"162","author":"AV Jablensky","year":"2005","unstructured":"Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich LA: Pregnancy delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry. 2005, 162: 79-91. 10.1176\/appi.ajp.162.1.79.","journal-title":"Am J Psychiatry"},{"key":"150_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/BF02245617","volume":"124","author":"CM Beasley Jr","year":"1996","unstructured":"Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996, 124: 159-167. 10.1007\/BF02245617.","journal-title":"Psychopharmacology (Berl)"},{"key":"150_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0165-0327(00)00303-7","volume":"67","author":"M Tohen","year":"2001","unstructured":"Tohen M, Zhang F, Keck PE, Feldman PD, Risser RC, Tran PV, Breier A: Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. J Affect Disord. 2001, 67: 133-140. 10.1016\/S0165-0327(00)00303-7.","journal-title":"J Affect Disord"},{"key":"150_CR8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","volume":"164","author":"M Tohen","year":"2007","unstructured":"Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann RW, Biederman J: Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007, 164: 1547-1556. 10.1176\/appi.ajp.2007.06111932.","journal-title":"Am J Psychiatry"},{"key":"150_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","volume":"48","author":"L Kryzhanovskaya","year":"2009","unstructured":"Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M: Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009, 48: 60-70. 10.1097\/CHI.0b013e3181900404.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"150_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4088\/JCP.08m03538","volume":"70","author":"LA Kryzhanovskaya","year":"2009","unstructured":"Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW: The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry. 2009, 70: 247-258. 10.4088\/JCP.08m03538.","journal-title":"J Clin Psychiatry"},{"key":"150_CR11","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1176\/appi.ajp.2007.06111886","volume":"164","author":"DJ Newport","year":"2007","unstructured":"Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, Knight BT, Gibson BB, Viguera AC, Owens MJ, Nemeroff CB, Stowe ZN: Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007, 164: 1214-1220. 10.1176\/appi.ajp.2007.06111886.","journal-title":"Am J Psychiatry"},{"key":"150_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0091-3057(02)00727-X","volume":"72","author":"H Rosengarten","year":"2002","unstructured":"Rosengarten H, Quartermain D: Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats. Pharmacol Biochem Behav. 2002, 72: 575-579. 10.1016\/S0091-3057(02)00727-X.","journal-title":"Pharmacol Biochem Behav"},{"key":"150_CR13","volume-title":"Congenital anomalies","author":"World Health Organization","year":"2013","unstructured":"World Health Organization: Congenital anomalies. 2013,\n                    http:\/\/www.who.int\/topics\/congenital_anomalies\/en\/index.html\n                    \n                  ,"},{"key":"150_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0020-7292(02)00197-2","volume":"78","author":"American College of Obstetricians and Gynecologists","year":"2002","unstructured":"American College of Obstetricians and Gynecologists: ACOG practice bulletin. Management of recurrent pregnancy loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 2002, 78: 179-190.","journal-title":"Int J Gynaecol Obstet"},{"key":"150_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00002018-200427060-00001","volume":"27","author":"KE Shields","year":"2004","unstructured":"Shields KE, Wiholm BE, Hostelley LS, Striano LF, Arena SR, Sharrar RG: Monitoring outcomes of pregnancy following drug exposure. Drug Saf. 2004, 27: 353-367. 10.2165\/00002018-200427060-00001.","journal-title":"Drug Saf"},{"key":"150_CR16","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1097\/01.AOG.0000158860.26939.2d","volume":"105","author":"SK Van Den Eeden","year":"2005","unstructured":"Van Den Eeden SK, Shan J, Bruce C, Glasser M: Ectopic pregnancy rate and treatment utilization in a large managed care organization. Obstet Gynecol. 2005, 105: 1052-1057. 10.1097\/01.AOG.0000158860.26939.2d.","journal-title":"Obstet Gynecol"},{"key":"150_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(05)67103-6","volume":"366","author":"CM Farquhar","year":"2005","unstructured":"Farquhar CM: Ectopic pregnancy. Lancet. 2005, 366: 583-591. 10.1016\/S0140-6736(05)67103-6.","journal-title":"Lancet"},{"key":"150_CR18","first-page":"46","volume":"44","author":"Centers for Disease Control and Prevention (CDC)","year":"1995","unstructured":"Centers for Disease Control and Prevention (CDC): Ectopic pregnancy \u2013 United States, 1990 1992. MMWR Morb Mortal Wkly Rep. 1995, 44: 46-48.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"150_CR19","first-page":"1","volume":"56","author":"SJ Ventura","year":"2008","unstructured":"Ventura SJ, Abma JC, Mosher WD, Henshaw SK: Estimated pregnancy rates by outcome for the United States, 1990\u20132004. Natl Vital Stat Rep. 2008, 56: 1-25. 28","journal-title":"Natl Vital Stat Rep"},{"key":"150_CR20","first-page":"1","volume":"57","author":"M Heron","year":"2009","unstructured":"Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B: Births: final data for 2006. Natl Vital Stat Rep. 2009, 57: 1-134.","journal-title":"Natl Vital Stat Rep"},{"key":"150_CR21","first-page":"1","volume":"57","author":"MF MacDorman","year":"2009","unstructured":"MacDorman MF, Kirmeyer S: Fetal and perinatal mortality, United States, 2005. Natl Vital Stat Rep. 2009, 57: 1-19.","journal-title":"Natl Vital Stat Rep"},{"key":"150_CR22","first-page":"1","volume":"16","author":"MF MacDorman","year":"2009","unstructured":"MacDorman MF, Kirmeyer S: The challenge of fetal mortality. NCHS Data Brief. 2009, 16: 1-8.","journal-title":"NCHS Data Brief"},{"key":"150_CR23","first-page":"1","volume":"57","author":"Centers for Disease Control","year":"2008","unstructured":"Centers for Disease Control: Update on overall prevalence of major birth defects \u2013 Atlanta, Georgia, 1978\u20132005. MMWR Morb Mortal Wkly Rep. 2008, 57: 1-5.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"150_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1136\/bmj.38919.495718.AE","volume":"333","author":"JL Zhu","year":"2006","unstructured":"Zhu JL, Basso O, Obel C, Bille C, Olsen J: Infertility, infertility treatment, and congenital malformations: Danish national birth cohort. BMJ. 2006, 333: 679-10.1136\/bmj.38919.495718.AE.","journal-title":"BMJ"},{"key":"150_CR25","unstructured":"Eli Lilly and Company: Zyprexa\u00ae (olanzapine) US prescribing information.\n                    http:\/\/pi.lilly.com\/us\/zyprexa-pi.pdf\n                    \n                  ,"},{"key":"150_CR26","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJM199804163381607","volume":"338","author":"G Koren","year":"1998","unstructured":"Koren G, Pastuszak A, Ito S: Drugs in pregnancy. N Engl J Med. 1998, 338: 1128-1137. 10.1056\/NEJM199804163381607.","journal-title":"N Engl J Med"},{"key":"150_CR27","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(99)04411-6","volume":"354","author":"B Bar-Oz","year":"1999","unstructured":"Bar-Oz B, Moretti ME, Mareels G, Van Tittelboom T, Koren G: Reporting bias in retrospective ascertainment of drug-induced embryopathy. Lancet. 1999, 354: 1700-1701. 10.1016\/S0140-6736(99)04411-6.","journal-title":"Lancet"},{"key":"150_CR28","volume-title":"Guidance for industry establishing pregnancy registries. Pregnancy Registry Working Group Pregnancy Labeling Taskforce","author":"EM Rodriguez","year":"2000","unstructured":"Rodriguez EM: Guidance for industry establishing pregnancy registries. Pregnancy Registry Working Group Pregnancy Labeling Taskforce. 2000,\n                    http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/slides\/3601s1e\/sld001.htm\n                    \n                  ,"},{"key":"150_CR29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1471-0528.2008.01701.x","volume":"115","author":"DJ Newport","year":"2008","unstructured":"Newport DJ, Brennan PA, Green P, Ilardi D, Whitfield TH, Morris N, Knight BT, Stowe ZN: Maternal depression and medication exposure during pregnancy: comparison of maternal retrospective recall to prospective documentation. BJOG. 2008, 115: 681-688. 10.1111\/j.1471-0528.2008.01701.x.","journal-title":"BJOG"},{"key":"150_CR30","unstructured":"US Food and Drug Administration: Reviewer Guidance: Evaluation of human pregnancy outcome data.\n                    http:\/\/www.fda.gov\/ohrms\/dockets\/98fr\/991540gd.pdf\n                    \n                  ,"},{"key":"150_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/01.WON.0000326657.57939.c9","volume":"35","author":"M Clark","year":"2008","unstructured":"Clark M: Retrospective versus prospective cohort study designs for evaluating treatment of pressure ulcers. A comparison of 2 studies. J Wound Ostomy Continence Nurs. 2008, 35: 391-394. 10.1097\/01.WON.0000326657.57939.c9.","journal-title":"J Wound Ostomy Continence Nurs"},{"key":"150_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.eurpsy.2006.01.014","volume":"21","author":"M Arora","year":"2006","unstructured":"Arora M, Praharaj SK: Meningocele and ankyloblepharon following in utero exposure to olanzapine. Eur Psychiatry. 2006, 21: 345-346. 10.1016\/j.eurpsy.2006.01.014.","journal-title":"Eur Psychiatry"},{"key":"150_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00737-006-0138-8","volume":"9","author":"AC Spyropoulou","year":"2006","unstructured":"Spyropoulou AC, Zervas IM, Soldatos CR: Hip dysplasia following a case of olanzapine exposed pregnancy: a questionable association. Arch Womens Ment Health. 2006, 9: 219-222. 10.1007\/s00737-006-0138-8.","journal-title":"Arch Womens Ment Health"},{"key":"150_CR34","first-page":"88","volume":"20","author":"R Ramkisson","year":"2008","unstructured":"Ramkisson R, Campbell M, Agius M: The clinical dilemma\u2013prescribing in pregnancy. Psychiatr Danub. 2008, 20: 88-90.","journal-title":"Psychiatr Danub"},{"key":"150_CR35","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1176\/appi.ajp.2007.07010176","volume":"164","author":"Y Yeshayahu","year":"2007","unstructured":"Yeshayahu Y: The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities. Am J Psychiatry. 2007, 164: 1759-1760.","journal-title":"Am J Psychiatry"},{"key":"150_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4088\/JCP.v66n0307","volume":"66","author":"O Diav-Citrin","year":"2005","unstructured":"Diav-Citrin O, Schechtman S, Ornoy S, Arnon J, Schaefer C, Garbis H, Clementi M, Ornoy A: Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry. 2005, 66: 317-322. 10.4088\/JCP.v66n0307.","journal-title":"J Clin Psychiatry"},{"key":"150_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1192\/bjp.bp.107.041541","volume":"192","author":"JJ Newham","year":"2008","unstructured":"Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH: Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008, 192: 333-337. 10.1192\/bjp.bp.107.041541.","journal-title":"Br J Psychiatry"},{"key":"150_CR38","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1046\/j.1440-1681.1999.03111.x","volume":"26","author":"S Schenker","year":"1999","unstructured":"Schenker S, Yang Y, Mattiuz E, Tatum D, Lee M: Olanzapine transfer by human placenta. Clin Exp Pharmacol Physiol. 1999, 26: 691-697. 10.1046\/j.1440-1681.1999.03111.x.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"150_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1017\/S1461145702003012","volume":"5","author":"S Croke","year":"2002","unstructured":"Croke S, Buist A, Hackett LP, Ilett KF, Norman TR, Burrows GD: Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol. 2002, 5: 243-247.","journal-title":"Int J Neuropsychopharmacol"},{"key":"150_CR40","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1176\/appi.ajp.160.8.1428","volume":"160","author":"SJ Gardiner","year":"2003","unstructured":"Gardiner SJ, Kristensen JH, Begg EJ, Hackett LP, Wilson DA, Ilett KF, Kohan R, Rampono J: Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants. Am J Psychiatry. 2003, 160: 1428-1431. 10.1176\/appi.ajp.160.8.1428.","journal-title":"Am J Psychiatry"},{"key":"150_CR41","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2190\/MTXF-06M3-DBFE-WPQJ","volume":"33","author":"SH Friedman","year":"2003","unstructured":"Friedman SH, Rosenthal MB: Treatment of perinatal delusional disorder: a case report. Int\u2019l. J. Psychiatry in Medicine. 2003, 33: 391-394. 10.2190\/MTXF-06M3-DBFE-WPQJ.","journal-title":"Int\u2019l. J. Psychiatry in Medicine"},{"key":"150_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/FTD.0b013e31816850e2","volume":"30","author":"UC Lutz","year":"2008","unstructured":"Lutz UC, Wiatr G, Orlikowsky T, Gaertner HJ, Bartels M: Olanzapine treatment during breast feeding: a case report. Ther Drug Monit. 2008, 30: 399-401. 10.1097\/FTD.0b013e31816850e2.","journal-title":"Ther Drug Monit"},{"key":"150_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881108096504","volume":"24","author":"A Whitworth","year":"2010","unstructured":"Whitworth A, Stuppaeck C, Yazdi K, Kralovec K, Geretsegger C, Zernig G, Alchhorn W: Olanzapine and breast-feeding: changes of plasma concentrations of olanzapine in a breast-fed infant over a period of 5 months. J Psychopharmacol. 2010, 24: 121-123. 10.1177\/0269881108096504.","journal-title":"J Psychopharmacol"},{"key":"150_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/bfm.2010.0027","volume":"6","author":"O Gilad","year":"2011","unstructured":"Gilad O, Merlob P, Stahl B, Klinger G: Outcome of infants exposed to olanzapine during breastfeeding. Breastfeed Med. 2011, 6: 55-58. 10.1089\/bfm.2010.0027.","journal-title":"Breastfeed Med"},{"issue":"Suppl C","key":"150_CR45","doi-asserted-by":"publisher","first-page":"C40","DOI":"10.1016\/S0149-2918(98)80007-6","volume":"20","author":"SA Goldman","year":"1998","unstructured":"Goldman SA: Limitations and strengths of spontaneous reports data. Clin Ther. 1998, 20 (Suppl C): C40-C44.","journal-title":"Clin Ther"},{"key":"150_CR46","volume-title":"Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns","author":"US Food and Drug Administration: FDA Drug Safety Communication","year":"2011","unstructured":"US Food and Drug Administration: FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. 2011,\n                    http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm243903.htm\n                    \n                  ,"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2050-6511-14-38\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-38.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-38","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-38.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T03:47:18Z","timestamp":1548128838000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/2050-6511-14-38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1186\/2050-6511-14-38","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,1]]},"article-number":"38"}}